|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||315.413 g·mol−1|
|3D model (JSmol)|
25D-NBOMe (or NBOMe-2C-D) is a derivative of the phenethylamine derived hallucinogen 2C-D. It acts in a similar manner to related compounds such as 25I-NBOMe, which is a potent agonist at the 5HT2A receptor. 25D-NBOMe has been sold as a street drug since 2010 and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe. It was banned as a Temporary Class Drug in the UK on 10 June 2013 after concerns about its recreational use.
As of October 2015 25D-NBOMe is a controlled substance in China.
Sveriges riksdag added 25D-NBOMe to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of Aug 1, 2013, published by Medical Products Agency in their regulation LVFS 2013:15 listed as 25D-NBOMe 2-(2,5-dimetoxi-4-metylfenyl)-N-(2-metoxibensyl)etanamin.
Unregulated at a federal and state level, though arguably may contravene the Federal Analog Act under certain circumstances given its structural and functional similarity to controlled substance 2C-D.
(and close relatives)
|This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.|